Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from BioNTech

Research behind COVID vaccines reaps close to $1 billion in royalties for Penn

PHILADELPHIA — The University of Pennsylvania has reaped extraordinary financial gain from COVID-19 vaccines — approaching $1 billion since the beginning of last year — thanks to patents on a process Penn researchers developed more than 15 years ago.

The Philadelphia Inquirer

BioNTech Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on BioNTech. Looking at options history for BioNTech (NASDAQ:BNTX) we detected 14 strange trades.

Benzinga

Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Nod For Kids As Young As Six Months

The FDA has granted emergency use authorization (EUA) to Pfizer Inc (NYSE:PFE) and BioNTech SE's (NASDAQ:BNTX) COVID-19 Vaccine as a three 3-µg dose series for children six months through 4 years of age. Based on safety, tolerability, and immunogenicity data, the 3-µg dose was carefully selected as the preferred dose for children under five. The EUA…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

BioNTech Whale Trades For June 10

A whale with a lot of money to spend has taken a noticeably bearish stance on BioNTech. Looking at options history for BioNTech (NASDAQ:BNTX) we detected 10 strange trades.

Benzinga

Breakthrough vaccine raises hopes of pancreatic cancer cure

Experts say vaccines could train the immune system to kill cells associated with pancreatic cancer

Wales Online

Breakthrough vaccine could help cure pancreatic cancer

Early trial results suggest personalised vaccines could stop deadly disease returning

The Independent UK

Pfizer submits COVID-19 shot for children under 5 for FDA authorization

WASHINGTON — Pfizer Inc. asked U.S. regulators to clear its COVID-19 vaccine for emergency use in children under age 5, an effort to extend protection against the virus to the country’s youngest.

Tribune News Service

Read news from The Economist, FT, and more,
with one subscription

Pfizer COVID shot seems protective for children under 5 in early data

Pfizer Inc. and BioNTech SE said their COVID-19 vaccine was highly effective and prompted a strong immune response in children under age 5, based on early results from a trial that is likely to pave the way for infants and toddlers to finally get immunized.

Tribune News Service

Covid vaccine: Pfizer says three doses enough to protect children under 5

Three doses of Pfizer’s Covid-19 vaccine will offer strong protection for children younger than 5, the company announced on Monday.

Evening Standard

Pfizer/BioNTech say 3 COVID shots elicit good response in children under 5

Drugmakers Pfizer Inc and BioNTech SE said on Monday that three doses of their COVID-19 vaccine generated a strong immune response in children under age 5 and was safe and well-tolerated in their clinical trial.

Reuters

Pfizer says 3 COVID shots protect children under 5

Pfizer says three small doses of its COVID-19 vaccine protect kids under 5 and that it plans to give the data to U.S. regulators later this week

The Independent UK

Omicron infection turbo-charges vaccinated people’s immunity: study

People who are vaccinated and then get infected with Omicron may be primed to overcome a broad range of coronavirus variants, early research suggests.

Bangkok Post

Where BioNTech Stands With Analysts

Within the last quarter, BioNTech (NASDAQ:BNTX) has observed the following analyst ratings:

Benzinga

Why BioNTech Stock Is Rising Today

BioNTech SE (NASDAQ: BNTX) shares are trading higher Monday after the company reported financial results and reaffirmed its 2022 outlook.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

BioNTech Clocks Over $6B In Q1 Sales, Sticks To FY22 Guidance

BioNTech SE (NASDAQ:BNTX) has reported Q1 FY22 revenues of €6.37 billion compared to €2.05 billion a year ago, mainly due to high demand for the company's COVID-19 vaccine. In Q1 FY22, BioNTech and its partner Pfizer Inc (NYSE:PFE) have invoiced approximately 750 million COVID-19 vaccine doses. As of end-April 2022, the companies have signed orders…

Benzinga

How To Attend BioNTech Q1 2022 Earnings Conference Call

BioNTech (NASDAQ:BNTX) will host a conference call at 08:00 AM ET on May 9, 2022, to discuss Q1 2022 earnings results. How to Attend BioNTech (BNTX) Conference Call Follow this link to access the live webcast.

The Guardian - UK

Pfizer accused of Covid profiteering as first-quarter sales hit $26bn

Pharma firm criticised over pricing and for keeping monopoly control over vaccine and new Paxlovid pill

Benzinga

The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis

Here's a roundup of top developments in the biotech space over the last 24 hours.

Get all your
news in one place.

100’s of premium titles.
One news app.

Salon

Another delay for five-and-under vaccine

The issue isn't around safety, but instead messaging and vaccine effectiveness

Benzinga

What's Happening With BioNTech SE Shares?

Shares of vaccine companies, including BioNTech SE - ADR (NASDAQ: BNTX), are trading higher amid COVID-19 concerns due to rising cases in China.

Benzinga

If You Invested $1,000 In BioNTech Stock At Its Pandemic Low, Here's How Much You'd Have Now

Investors who bought stocks during the COVID-19 market crash in 2020 have generally experienced some big gains in the past two years. But there is no question some big-name stocks performed better than others since the pandemic bottom.

Benzinga

Pfizer/BioNTech's COVID-19 Vaccine Booster Shows High Immune Response In Kids Aged 5-11 Years

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have announced results from a Phase 2/3 trial of a 10 µg booster (third) dose of COVID-19 vaccine in children aged 5-11 years.

Reuters

Pfizer/BioNTech say booster dose increases protection vs Omicron in kids aged 5-11

A third dose of the COVID-19 vaccine from Pfizer Inc and BioNTech produced significant protection against the Omicron variant of the coronavirus in healthy children ages 5 to 11, the companies said on Thursday.

Benzinga

HC Wainwright Reiterates Buy Rating On BioNTech, While Lowers Price Target

HC Wainwright has reiterated its Buy rating on BioNTech SE (NASDAQ: BNTX) while reducing the price tar

Benzinga

Expert Ratings for BioNTech

Within the last quarter, BioNTech (NASDAQ:BNTX) has observed the following analyst ratings:

1 … 5 6 7 8

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

University of Pennsylvania

119 stories

University of Washington

European Medicines Agency

76 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.